Showing 4461-4470 of 5302 results for "".
- Sensus Healthcare Launches New Line of Laser Systems for Clinical and Aesthetic Dermatologyhttps://practicaldermatology.com/news/sensus-healthcare-launches-new-line-of-laser-systems-for-clinical-and-aesthetic-dermatology/2457846/Sensus Healthcare, Inc. has launched Sensus Laser Systems, a unique multi-platform line of high-quality, cost-effective dermatological lasers to complement its existing superficial radiation therapy (SRT) system, which is used for non-invasive treatment of non-melanoma skin cancers and keloids. T
- CareCredit Moves Into Day and Med Spa Marketshttps://practicaldermatology.com/news/carecredit-moves-into-day-and-med-spa-markets/2457847/CareCredit is expanding into the day and medical spa markets. As part of this new program, CareCredit partnered with both the American Med Spa Association and the Spa Industry Association to bring the benefits of CareCredit to their practices. Providers can now offer clients acces
- Medimetriks Divests Xepi Cream to Cutanea Life Scienceshttps://practicaldermatology.com/news/medimetriks-divests-xepi-cream-to-cutanea-life-sciences/2457850/Medimetriks Pharmaceuticals, Inc. divested exclusive US rights for Xepi (ozenoxacin cream) 1% to Cutanea Life Sciences, Inc. for up to $30 million, with $29 million to be paid in 2018, plus the assumption of $5 mil
- Botox Biosimilar in the Workshttps://practicaldermatology.com/news/botox-biosimilar-in-the-works/2457853/Mylan N.V. and Revance Therapeutics, Inc. are partnering to develop a biosimilar to BOTOX® (onabotulinumtoxinA). "We have reviewed the work done to date by Revance and we are extremely excited and confident
- Skin Microbiome May Protect Against Skin Cancerhttps://practicaldermatology.com/news/skin-microbiome-may-protect-against-skin-cancer/2457857/Beneficial skin bacteria may protect against skin cancer, according to a new study in Science Advances. “We have identified a strain of Staphylococcus epidermidis, common on healthy human skin, that exerts a selective ability to inhibit the growth of some cancers,” sa
- Skin of Color Seminar Series to Provide Latest Research and Practical Pearls for Dermatologic Treatment of Skin of Colorhttps://practicaldermatology.com/news/skin-of-color-seminar-series-to-provide-latest-evidence-based-research-and-practical-pearls-for-dermatologic-treatment-of-skin-of-color/2457859/Now in its tenth year, the Skin of Color Seminar Series (SOCSS) will be the largest medical education event of 2018 dedicated to providing dermatologists with evidence-based research and practical pearls in treating skin of color, including patients with multiracial backgrounds. SOCSS, which will
- Burt's Bees Nature-Based Sensitive Skin Regimen Trumps Dermatologist-recommended Regimenhttps://practicaldermatology.com/news/burts-bees-nature-based-sensitive-skin-regimen-trumps-dermatologist-recommended-regimen/2457860/Burt's Bees nature-based sensitive line outperformed a dermatologist-recommended synthetic control regimen in a study of 120 people with clinically diagnosed sensitive skin from rosacea, atopic dermatitis/eczema, or cosmetic intolerance. The nat
- HA Collagen Booster Available from BrandMDhttps://practicaldermatology.com/news/ha-collagen-booster-available-from-brandmd/2457862/HA Collagen Booster, now available from BrandMD, contains a proprietary and technologically advanced combination of hyaluronic acid. This innovative formulation has been clinically trialed and yields excellent results, according to the company The product itself contains four various form
- MainPointe Pharmaceuticals to Purchase and License Mission's Consumer Productshttps://practicaldermatology.com/news/mainpointe-pharmaceuticals-to-purchase-and-license-missions-consumer-products/2457868/Mission Pharmacal Company has recently divested several consumer products to MainPointe Pharmaceuticals, LLC. In addition, the marketing rights of additional consumer products have been licensed by Mission to MainPointe. As part of these transactions, the companies have also entered into a renewa
- Ortho Dermatologics Presents Analysis of Siliq Phase 3 Data on Disease-Related Anxiety and Depression in Patients with Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-presents-analysis-of-siliq-phase-3-data-on-disease-related-anxiety-and-depression-in-patients-with-psoriasis/2457875/Ortho Dermatologics, a division of Valeant Pharmaceuticals North America, LLC, shared the results from an analysis of the Phase 3 clinical trial AMAGINE-1, which evaluated mental health comorbidities associated with psoriasis, such as anxiety and depression. These findings were presented for the